SNDL Finalizes Parallel Assets Acquisition, Boosting U.S. Medical Cannabis Market Presence

Overview of the Parallel Asset Acquisition

SNDL has confirmed the completion of its acquisition of selected assets from Surterra Holdings, Inc., a vertically integrated cannabis operator based in the U.S. Known as the Parallel Transaction, this deal was first announced on April 29, 2026, and has now been finalized through a strict foreclosure agreement involving SH Parent, Inc. and CDXX TransCo, LLC among others.

This transaction grants SNDL indirect majority economic exposure to TransactionCo, which manages Surterra Holdings’ operations in key U.S. states. The acquisition is a crucial step in SNDL’s plan to strengthen its position as a leading entity in the North American cannabis industry.

Strategic Significance of the Acquisition

Acquiring the Parallel assets is a strategic move for SNDL to expand its footprint in the U.S. medical cannabis market. The company anticipates converting its indirect exposure into direct, consolidated ownership in the near future, pending regulatory and legal approvals. This transition could establish SNDL as one of the first Nasdaq-listed firms with direct U.S. medical cannabis operations.

CEO Zach George emphasized that this acquisition represents a defining milestone, with SNDL now operating the world’s largest cannabis retail network by store count at 249 locations. The company plans to leverage its extensive experience in the competitive Canadian cannabis market to support its U.S. expansion.

Details on the Acquired Operations

The Parallel assets include 56 retail dispensaries and three cultivation and manufacturing facilities spread across Florida, Texas, and Massachusetts. These assets provide a strong foundation for SNDL to accelerate growth and improve profitability in the U.S. market.

In Florida, SNDL acquired 43 dispensaries under the Surterra Wellness brand, supported by a significant cultivation facility. Texas operations include 10 retail outlets under the Goodblend brand, one of only three licensed operators in the state. Additionally, the acquisition adds three dispensaries in Massachusetts, expanding SNDL’s presence in a rapidly growing cannabis market.

Financial Impact of the Parallel Transaction

The immediate financial effect of the Parallel Transaction on SNDL’s reporting is limited; however, the acquisition includes a principal loan position of US$29.75 million, obtained at a discount. This investment continues to be accounted for using the equity method under International Financial Reporting Standards, reflecting SNDL’s indirect economic interest in the assets.

Future financial reporting changes are expected once SNDL transitions to direct majority equity and debt ownership, which will likely result in operational control and consolidation of TransactionCo’s medical cannabis business. This process remains subject to legal and regulatory conditions.

Background and Purpose of the Acquisition

The Parallel Transaction arose from a complex restructuring involving Talladega LP, which originally provided Parallel with a US$150 million secured loan in 2021. Following a loan default, a foreclosure agreement was executed, leading to SNDL’s acquisition of the assets. This deal effectively eliminated approximately US$842 million in debt obligations tied to Parallel, creating a more sustainable capital structure.

The acquisition aims not only to reduce Parallel’s legacy debt but also to position SNDL for growth in key U.S. markets by leveraging operational expertise and capital resources to generate long-term shareholder value.

Prospects for Growth in U.S. Cannabis Markets

With the Parallel Transaction complete, SNDL is well-positioned to pursue substantial growth opportunities in the U.S. medical cannabis markets, focusing on Florida, Texas, and Massachusetts, each with distinct market dynamics and consumer bases.

SNDL plans to apply insights gained from the competitive Canadian cannabis industry to navigate U.S. regulatory complexities and market challenges, enabling disciplined expansion and strategic consolidation to enhance shareholder returns.

Legal and Regulatory Factors

The acquisition and future consolidation of Parallel assets are subject to various legal and regulatory approvals. SNDL must comply with applicable laws and Nasdaq listing standards as it moves from indirect to direct ownership.

Any potential exposure to adult-use or recreational cannabis, particularly in Massachusetts, is expected to remain deconsolidated until regulatory and accounting standards allow alternative treatment. This cautious approach underscores SNDL’s commitment to compliance while pursuing growth.

Advisory Roles in the Transaction

SNDL was advised by Weil, Gotshal & Manges LLP as legal counsel, and Moelis & Company served as exclusive financial advisor and investment banker. Their expertise was critical in managing the complexities of the Parallel Transaction and ensuring its successful completion.

The involvement of these advisors highlights the strategic importance of the acquisition and SNDL’s dedication to executing its growth plans effectively.

Summary of the Parallel Transaction

The completion of the Parallel Transaction represents a major milestone for SNDL, enhancing its operational capabilities and positioning the company for growth in the U.S. medical cannabis market. With an expanded retail network and cultivation facilities, SNDL is well-equipped to capitalize on the evolving cannabis industry.

Investors will closely monitor the integration of the acquired assets and SNDL’s financial performance in upcoming quarters. The strategic choices following this acquisition will be pivotal in shaping SNDL’s future in the competitive cannabis landscape.